Recurrent giant cell carcinoma of the bladder

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

European urology·2026

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

European urology·2026

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

European urology·2025

Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.

Nature reviews. Urology·2025

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Nature medicine·2025

Post-Diagnostic Red Meat, Poultry, and Egg Intake and Risk of Prostate Cancer Progression and Mortality: A Systematic Review.

The Journal of urology·2026

Second Time's a Charm? A Matched Case-Control Analysis of Revision Urethroplasty versus Primary Urethroplasty.

The Journal of urology·2026

Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis.

The Journal of urology·2026

Functional analysis of Candida albicans protein kinases identifies Crk1 as a modulator of epithelial cell damage.

mBio·2026

In vivo screen for osteoclast derived osteogenic factors using non-resorptive osteoclasts in zebrafish bone.

G3 (Bethesda, Md.)·2026

The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.

Frontiers in cellular and infection microbiology·2026

Oncometabolites in Cancer Metabolism: Mechanistic Insights and Biomarker Potential- A Narrative Review.

Health science reports·2026

Correction to "Homeobox B13 activates the hypoxia-inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma".

Journal of cell communication and signaling·2026

The application and progress of AI-based image analysis in tumor organoid research.

iScience·2026

Related Experiment Videos

Recurrent giant cell carcinoma of the bladder

Related Concept Videos

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Post-Diagnostic Red Meat, Poultry, and Egg Intake and Risk of Prostate Cancer Progression and Mortality: A Systematic Review.

Second Time's a Charm? A Matched Case-Control Analysis of Revision Urethroplasty versus Primary Urethroplasty.

Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis.

Functional analysis of Candida albicans protein kinases identifies Crk1 as a modulator of epithelial cell damage.

In vivo screen for osteoclast derived osteogenic factors using non-resorptive osteoclasts in zebrafish bone.

The microbiota-host metabolic axis in cervical cancer: from homeostatic disruption to mechanisms of therapy resistance.

Oncometabolites in Cancer Metabolism: Mechanistic Insights and Biomarker Potential- A Narrative Review.

Correction to "Homeobox B13 activates the hypoxia-inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma".

The application and progress of AI-based image analysis in tumor organoid research.

Related Experiment Videos

Recurrent giant cell carcinoma of the bladder

Related Concept Videos

Related Articles